Endologix, Inc. (ELGX)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Endologix, Inc. (ELGX) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011162
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月21日
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Endologix, Inc. (Endologix) is a medical device company. It undertakes the development, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). The company’s AAA products are built on traditional minimally-invasive endovascular repair (EVAR) platform or endovascular sealing (EVAS) platform. The company’s EVAR products include AFX endovascular AAA system Vela Proximal Endograft and Intuitrak endovascular AAA system; and EVAS products comprise Nellix endovascular aneurysm sealing system. It has manufacturing facility in Irvine. The company sells its products to hospitals in the US and Europe through direct sales force and through third-party international distributors and agents in other parts of the world. Endologix is headquartered in California, the US.

Endologix, Inc. (ELGX) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Endologix, Inc., Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Endologix, Inc., Medical Equipment Deals By Type, 2011 to YTD 2017 7
Endologix, Inc., Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Endologix, Inc., Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Endologix, Inc., Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Endologix, Inc., Medical Equipment, Deal Details 12
Venture Financing 12
TriVascular Raises US$2 Million In Venture Financing 12
TriVascular Raises US$40 Million In Series E Financing 13
Trivascular Raises Funds Through Initial Tranche Of Series D Financing 15
TriVascular Raises US$7.2 Million In Venture Financing 17
Partnerships 18
Endologix Enters into Co-Development Agreement with Japan Lifeline 18
Equity Offering 19
Endologix Plans to Raise USD46.2 Million in Equity Offering of Shares 19
TriVascular Technologies Completes IPO For US$89.7 Million 20
Endologix Completes Public Offering Of Common Stock For US$40 Million 22
Debt Offering 23
Endologix Raises USD125 Million in Public Offering of 3.25% Notes Due 2020 23
TriVascular Raises USD10 Million in Private Placement 25
Endologix Completes Public Offering Of Notes Due 2018 For US$86.3 Million 26
Acquisition 28
Endologix Acquires TriVascular Technologies 28
Endologix, Inc. – Key Competitors 30
Endologix, Inc. – Key Employees 31
Endologix, Inc. – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 07, 2017: Endologix Reports Third Quarter 2017 Financial Results 33
Aug 02, 2017: Endologix Reports Second Quarter 2017 Financial Results 34
May 04, 2017: Endologix Reports First Quarter 2017 Financial Results 35
Feb 22, 2017: Endologix Reports Results for the Fourth Quarter and Full Year 2016 36
Nov 01, 2016: Endologix Reports Results for the Third Quarter 2016 38
Aug 02, 2016: Endologix Reports Results for the Second Quarter 2016 40
May 09, 2016: Endologix Reports Results for the First Quarter 2016 42
Feb 22, 2016: Endologix Reports Results for the Fourth Quarter and Full Year 2015 44
Corporate Communications 46
Oct 19, 2017: Endologix Appoints John Onopchenko as Chief Operating Officer 46
Feb 06, 2017: Endologix Announces Appointment of Dan Lemaitre as Chairman of the Board 47
Oct 25, 2016: Endologix Appoints Matthew Thompson, M.D., as Chief Medical Officer 48
Product News 49
03/08/2016: Endologix Announces First Patients in Japan Treated With Nellix EndoVascular Aneurysm Sealing System 49
02/29/2016: Endologix Announces First U.S. Commercial Implant of AFX2 Bifurcated Endograft System 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Endologix, Inc., Medical Equipment, Key Facts, 2016 2
Endologix, Inc., Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Endologix, Inc., Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Endologix, Inc., Medical Equipment Deals By Type, 2011 to YTD 2017 7
Endologix, Inc., Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Endologix, Inc., Deals By Market, 2011 to YTD 2017 9
Endologix, Inc., Medical Equipment, Deals Summary, 2011 to YTD 2017 10
TriVascular Raises US$2 Million In Venture Financing 12
TriVascular Raises US$40 Million In Series E Financing 13
Trivascular Raises Funds Through Initial Tranche Of Series D Financing 15
TriVascular Raises US$7.2 Million In Venture Financing 17
Endologix Enters into Co-Development Agreement with Japan Lifeline 18
Endologix Plans to Raise USD46.2 Million in Equity Offering of Shares 19
TriVascular Technologies Completes IPO For US$89.7 Million 20
Endologix Completes Public Offering Of Common Stock For US$40 Million 22
Endologix Raises USD125 Million in Public Offering of 3.25% Notes Due 2020 23
TriVascular Raises USD10 Million in Private Placement 25
Endologix Completes Public Offering Of Notes Due 2018 For US$86.3 Million 26
Endologix Acquires TriVascular Technologies 28
Endologix, Inc., Key Competitors 30
Endologix, Inc., Key Employees 31
Endologix, Inc., Subsidiaries 32

★海外企業調査レポート[Endologix, Inc. (ELGX)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Galera Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Galera Therapeutics Inc (Galera Therapeutics) is a clinical stage biotechnology company that discovers and develops novel cancer treatments. The company also concentrates on the prevention of radiation-induced toxicity including mucositis and the treatment of cancer. Its GC4419 is a selectiv …
  • Kobe Steel, Ltd.:戦略・SWOT・企業財務分析
    Kobe Steel, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kobe Steel, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Alliance Oil Co Ltd:企業の戦略的SWOT分析
    Alliance Oil Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Huawei Investment & Holding Co., Ltd.:企業の戦略・SWOT・財務情報
    Huawei Investment & Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Huawei Investment & Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • IAC/INTERACTIVECORP:企業の戦略・SWOT・財務分析
    IAC/INTERACTIVECORP - Strategy, SWOT and Corporate Finance Report Summary IAC/INTERACTIVECORP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • BYD Co Ltd (1211):企業の財務・戦略的SWOT分析
    BYD Co Ltd (1211) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Shanghai SECCO Petrochemical Co Ltd:企業の戦略的SWOT分析
    Shanghai SECCO Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Atlas Genetics Ltd:企業の製品パイプライン分析2018
    Summary Atlas Genetics Ltd (Atlas Genetics) is an in vitro diagnostics company that offers decentralised, near-patient and point of care testing services. The company develops and offers diagnostic platforms such as io system and callisto system. Its io system is a diagnostic instrument and disposab …
  • GS Yuasa Corporation (6674):企業の財務・戦略的SWOT分析
    GS Yuasa Corporation (6674) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Xinjiang Goldwind Science & Technology Co Ltd (002202):企業の財務・戦略的SWOT分析
    Xinjiang Goldwind Science & Technology Co Ltd (002202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • Bioxyne Ltd (BXN):企業の財務・戦略的SWOT分析
    Bioxyne Ltd (BXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Kindred Healthcare Inc (KND):製薬・医療:M&Aディール及び事業提携情報
    Summary Kindred Healthcare Inc (Kindred Healthcare) is a healthcare services provider with focus on post-acute care services. The company through its subsidiaries offers home health, hospice and community care services to patients in homes, nursing centers, and other residential settings. It operate …
  • SMART Global Holdings, Inc. (SGH):企業の財務・戦略的SWOT分析
    SMART Global Holdings, Inc. (SGH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Parexel International Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Parexel International Corp (Parexel) is a biopharmaceutical outsourcing service company which focuses on providing various services for managing the biopharmaceutical product lifecycle and for the development and commercialization of new medical therapies. It offers a comprehensive range of …
  • Cinemark Holdings Inc (CNK):企業の財務・戦略的SWOT分析
    Cinemark Holdings Inc (CNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Koki Holdings Co Ltd:企業の戦略的SWOT分析
    Koki Holdings Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Spirit AeroSystems Holdings, Inc.:企業のM&A・事業提携・投資動向
    Spirit AeroSystems Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Spirit AeroSystems Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Datatec Limited:企業の戦略・SWOT・財務分析
    Datatec Limited - Strategy, SWOT and Corporate Finance Report Summary Datatec Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Rex International Holding Ltd (5WH):企業の財務・戦略的SWOT分析
    Summary Rex International Holding Ltd (Rex International), formerly Rex International Holding Pte Ltd is an independent exploration and production oil company. The company develops oil and gas properties across Singapore. It operates substantial oil and gas exploration concessions in the UAE, Oman, …
  • EBS Technologies GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary EBS Technologies GmbH (EBS) is a medical device company that develops stimulation system for visual field effect. The company offers Eyetronic Therapy, which has been developed for patients suffering from a progressive visual field loss due to glaucoma and other diseases of the optic nerve. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆